Xi Wang

Xi Wang

Auto-generated profile, based on publicly available information

Xi Wang

CVS Health, Blue Bell, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2020 in Military Psychology
Verified
Journal Article
Open access
GKGirija Kaimal
Girija Kaimal
JJJacqueline P. Jones
Jacqueline P. Jones
RDRebekka Dieterich-Hartwell
Rebekka Dieterich-Hartwell
XWXi Wang
Xi Wang
Art therapy has been found to help Veterans with symptoms of post-traumatic stress. There is however limited scholarship on the differences in outcomes based on dosage (short-term vs. long-term treatment) especially for active duty military service members (SMs). This mixed methods program evaluation study examined feedback from SMs on their experiences of art therapy in an integrative medical care center after 3 weeks of group therapy and at the end of treatment (average time of 2 years). Data included participant demographics, feedback surveys, and narrative responses from SMs experiences of art therapy. The results indicate that longer-term art therapy resulted in improved perceived outcomes compared with the short term 3-week intervention. SMs with longer time in service reported the most improved self-reported outcomes. Women SMs expressed more positive emotions during their art making. Specific themes that were effectively addressed through art therapy included frustration tolerance, grief and loss, emotion regulation, personal insight, resiliency, and trauma processing. SMs also highlighted the unique and transformative role of the relationship with the therapist with alleviation of symptoms. The findings suggest benefits to long-term art therapy including improved ability in SMs to be aware of their symptoms and communicate effectively with others.

10 November 2023 in Drug and Alcohol Dependence Reports
Verified
Journal Article
Open access
XWXi Wang
Xi Wang
ZMZachary Meisel
Zachary Meisel
KKKatherine Kellom
Katherine Kellom
JWJennifer Whitaker
Jennifer Whitaker
DSDouglas Strane
Douglas Strane
MMMeredith Matone
Meredith Matone
Research gaps exist on the use of medications for opioid use disorder (OUD) among birthing people. This retrospective cohort study included people who underwent childbirth deliveries during 2017-2020 and had a diagnosis of OUD identified from a national private insurance claims database. Buprenorphine prescriptions received during the year before childbirth and the year after childbirth were obtained from pharmacy claims. Logistic regressions were used to estimate associations between receipt of buprenorphine and individual and state-level factors. Among a sample of 1,523 birthing people diagnosed with OUD, 540 (35.5 %) received buprenorphine during the pregnancy or postpartum periods. About half (51.5 %) of new recipients of buprenorphine received treatment for at least six months and, of those, one-third experienced a treatment interruption. The buprenorphine receipt rate differed significantly by race and ethnicity: 28.8 % of non-Hispanic Black birthing people with OUD and 22.8 % of Hispanic birthing people with OUD received buprenorphine treatment in contrast to 37.7 % of non-Hispanic white birthing people (aOR 0.53 [95 % CI 0.35-0.81] and 0.59 [95 % CI 0.37-0.96], respectively). The buprenorphine use rate increased over time from 29.7 % in 2017 to 42.9 % in 2020. Birthing people living in states with punitive policies related to substance use in pregnancy had the lowest buprenorphine use rate of 22.7 % as compared to 43.0 % in states with least restrictive policies. In this national sample of privately-insured individuals, by 2020, 42.9 % of birthing people with OUD received buprenorphine treatment. Treatment discontinuation and interruptions were common in the period surrounding childbirth.

19 March 2026 in BMJ Open
Verified
Journal Article
Open access
SASruthi Adimadhyam
Sruthi Adimadhyam
DLDominique Luyts
Dominique Luyts
DODriss Oraichi
Driss Oraichi
QDQuentin Deraedt
Quentin Deraedt
JPJean-Yves Pircon
Jean-Yves Pircon
NCNoelle Cocoros
Noelle Cocoros
Introduction: In May 2023, the US Food and Drug Administration (FDA) initially approved an AS01 E -adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine (adjuvanted RSVPreF3) for adults aged ≥60 years. The approval was expanded in June 2024 to include adults 50–59 years of age at increased risk for RSV-associated lower respiratory tract disease. In this paper, we describe the protocol of a postmarketing safety study evaluating the association between adjuvanted RSVPreF3 and new-onset Guillain-Barré syndrome (GBS), acute disseminated encephalomyelitis (ADEM) and atrial fibrillation (AF) among adults ≥50 years of age in the USA and provide our rationale for key methodological decisions. Methods and analysis: The potential associations between adjuvanted RSVPreF3 and GBS, ADEM and AF will be evaluated using secondary healthcare data and the self-controlled risk interval (SCRI) design. Data from five research partners in the USA spanning August 2023 through June 2030 will be used for the conduct of yearly monitoring queries and, sample size permitting, SCRI analyses. Claims-based definitions for new-onset outcomes (first diagnosis in 365 days) are: ≥1 inpatient diagnosis for GBS and ADEM; ≥1 inpatient or ≥2 ambulatory/emergency diagnoses for AF. The primary risk and control windows are 1–42 and 43–84 days, respectively, for GBS and ADEM; and 1–8 and 9–16 days for AF. SCRI analyses for GBS and ADEM will include chart-confirmed cases. SCRI analyses for AF will adjust for the positive predictive value obtained from validation against charts. Conditional Poisson regression will be used to calculate incidence rate ratios. Ethics and dissemination: This study was approved by the Institutional Review Boards (IRB) of Harvard Pilgrim Health Care Institute; WIRB-Copernicus Group, Inc and its affiliates (collectively, ‘WCG’); WCG IRB, Inc; and Sterling IRB, with Federal Wide Assurance (FWA) numbers FWA00000100, FWA00033319 and FWA00025632, respectively, for all participating research partners. Study results will be shared with the US FDA and publicly disseminated through national or international clinical or scientific conferences and peer-reviewed publications. Registration: This protocol has been registered in the Heads of Medicines Agencies–European Medicines Agency Real World Data Catalogues (EUPAS1000000486).

12 June 2024 in Children and Youth Services Review
Verified
Journal Article
Closed access
SGStephanie Garcia
Stephanie Garcia
KKKatherine S. Kellom
Katherine S. Kellom
PCPeter F. Cronholm
Peter F. Cronholm
XWXi Wang
Xi Wang
EPElizabeth Pride
Elizabeth Pride
MMMeredith Matone
Meredith Matone

16 July 2021
Verified
Thesis
Closed access
XWXi Wang
Xi Wang
NLNora Lee
Nora Lee
Objective: The objective of this project was to examine whether maternal pre-pregnancy body mass index (BMI) and gestational weight gain (GWG) are risk factors for autism spectrum disorders (ASD) and ASD-related symptoms (autistic traits) among offspring, and whether adverse obstetric outcomes can account for these associations. Methods: We used data from two population-based cohorts, the Avon Longitudinal Study of Parents and Children (ALSPAC) and the Stockholm Youth Cohort (SYC). The main-effect analysis included a sample of 11,199 mother-child pairs from the ALSPAC, a prospective cohort of births in the Bristol area of UK in 1991-1992. Children with ASD diagnosis were identified from multiple sources, including linkage to medical records, an educational database, and parental reports. The autistic traits included four individual measures (e.g., child's score of the Social and Communication Disorders Checklist) and seven standardized autistic factor scores that were derived from a previous factor analysis. The mediation analysis included a sample of 335,993 mother-child pairs from the Stockholm Youth Cohort, a record-linkage cohort comprising children born 1984-2007 and residing in Stockholm County, Sweden. ASD cases were identified from four national and regional registers. Potential mediators considered were adverse obstetric outcomes, including preterm birth, maternal complications during pregnancy (gestational diabetes, gestational hypertension, preeclampsia, eclampsia), cesarean section delivery, suction-assisted delivery, tongs-assisted delivery, and adverse neonatal outcomes (low birth weight, low Apgar score at 5 minutes after birth, small-/large-for-gestational-age). We used two mediation analysis methods under the counterfactual framework-G-computation method was used to analyze each mediator one at a time, and a weighting-based method was used to estimate the joint effect of multiple mediators. Results: In the ALSPAC, children born to obese mothers had lower (indicating worse performance and higher risk for ASD) mean factor scores of verbal abilities (beta estimate -0.11, 95% CI -1.19, -0.02), language acquisition (-0.09, 95% CI -0.18, -0.01) and semantic-pragmatic skills (-0.25, 95% CI -0.33, -0.17), compared to children born to normal-weight mothers. There was no evidence that maternal pre-pregnancy BMI was associated with other autistic trait measures nor the ASD diagnosis. In the SYC, we found that a small proportion of the total effect of insufficient GWG on offspring ASD was mediated by preterm birth, low birth weight, and small-for-gestational-age. For example, 15% of the total effect of insufficient GWG on ASD was mediated by low birth weight. There is no evidence showing that the total effect of pre-pregnancy overweight or obesity on offspring ASD risk were mediated by adverse obstetric outcomes. Conclusion: In a large population-based, birth cohort in the UK, we found weak associations between maternal pre-pregnancy overweight/obesity and offspring autistic traits that characterize the deficits in communication. We found no evidence supporting a relationship of maternal pre-pregnancy BMI and GWG with the risk of offspring ASD diagnosis. In a large prospective, register-based cohort in Sweden, we found some evidence that preterm, low birth weight, and small-for-gestational-age birth might partly account for the effect of insufficient GWG on offspring ASD risk. Given the complex manifestations of ASD, future studies on the relationship of maternal obesity and GWG with ASD should expand the outcome measures to dimensional autistic traits characterizing different components of ASD symptoms. It is also warranted for future studies on ASD etiology to apply mediation analysis methods under the counterfactual framework to explore the mechanisms underlying the effect of a risk factor for ASD.